TW202342511A - Sars-cov-2棘蛋白特異性抗體及其用途 - Google Patents

Sars-cov-2棘蛋白特異性抗體及其用途 Download PDF

Info

Publication number
TW202342511A
TW202342511A TW111150166A TW111150166A TW202342511A TW 202342511 A TW202342511 A TW 202342511A TW 111150166 A TW111150166 A TW 111150166A TW 111150166 A TW111150166 A TW 111150166A TW 202342511 A TW202342511 A TW 202342511A
Authority
TW
Taiwan
Prior art keywords
antibody
antigen
cov
binding fragment
amino acid
Prior art date
Application number
TW111150166A
Other languages
English (en)
Chinese (zh)
Inventor
林國儀
翁啟惠
王仕文
張毅軒
Original Assignee
中央研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中央研究院 filed Critical 中央研究院
Publication of TW202342511A publication Critical patent/TW202342511A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW111150166A 2021-12-27 2022-12-27 Sars-cov-2棘蛋白特異性抗體及其用途 TW202342511A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163266008P 2021-12-27 2021-12-27
US63/266,008 2021-12-27

Publications (1)

Publication Number Publication Date
TW202342511A true TW202342511A (zh) 2023-11-01

Family

ID=87000251

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111150166A TW202342511A (zh) 2021-12-27 2022-12-27 Sars-cov-2棘蛋白特異性抗體及其用途

Country Status (6)

Country Link
US (1) US20230279080A1 (enExample)
EP (1) EP4457243A4 (enExample)
JP (1) JP2025501775A (enExample)
CN (1) CN120787235A (enExample)
TW (1) TW202342511A (enExample)
WO (1) WO2023129928A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
CA3182526A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US20110250203A1 (en) * 2008-08-29 2011-10-13 Symphogen A/S Anti-cd5 antibodies
EP3347048B1 (en) * 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
US20190194345A1 (en) * 2015-10-05 2019-06-27 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
US11370842B2 (en) * 2017-08-01 2022-06-28 City Of Hope Anti-IL1RAP antibodies
CN110713537B (zh) * 2018-07-13 2023-04-21 江苏怀瑜药业有限公司 一种sema4d抗体及其制备方法和应用
CR20220552A (es) * 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno

Also Published As

Publication number Publication date
EP4457243A2 (en) 2024-11-06
WO2023129928A3 (en) 2023-08-10
WO2023129928A2 (en) 2023-07-06
US20230279080A1 (en) 2023-09-07
JP2025501775A (ja) 2025-01-23
CN120787235A (zh) 2025-10-14
EP4457243A4 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
US20230279080A1 (en) Antibody specific to spike protein of sars-cov-2 and uses thereof
US11866485B2 (en) Antibody specific to spike protein of SARS-CoV-2 and uses thereof
JP7013632B2 (ja) 自己免疫疾患を治療するための抗ｉｆｎａｒ１抗体
JP6943549B2 (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
CN113583116B (zh) 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途
AU2018210388C1 (en) Anti-HERV-K envelope antibody and uses thereof
CN114591434B (zh) 抗Siglec15抗体及其制备方法和用途
JP2023534922A (ja) ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子
EP4585687A1 (en) Human antibody against coronavirus variants or antigen-binding fragment thereof
EP4206224A1 (en) Human antibody or antigen-binding fragment thereof against coronavirus spike protein
WO2024189628A1 (en) Lag-3 inhibition for enhanced antiviral immune response
HK40126868A (en) Antibody specific to spike protein of sars-cov-2 and uses thereof
TWI868567B (zh) 冠狀病毒之特異性抗體及其用途
TWI877179B (zh) 抗-angpt2抗體
HK40111296A (en) Antibody specific to spike protein of sars-cov-2 and uses thereof
WO2026029035A1 (ja) コロナウイルス変異株に対するヒト抗体またはその抗原結合断片
CN118406140A (zh) 针对SARS-CoV-2及其突变株的广谱单克隆抗体及其用途
CN120769863A (zh) SARS-CoV-2刺突蛋白结合分子
WO2025238052A1 (en) Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
WO2023131262A1 (zh) 特异性结合SARS-CoV-2的抗原结合蛋白
US20240166745A1 (en) Lag-3 and pd-1/lag-3-antibodies
WO2024150074A2 (en) Coronavirus antibodies and therapeutic uses thereof
BR112020017605B1 (pt) Cadeia pesada, anticorpos anti-trem-1, molécula biespecífica, imunoconjugado, composição e kit dos mesmos